122 related articles for article (PubMed ID: 17942282)
1. Alteration in kidney glucose and amino acids are implicated in renal pathology in MRL/lpr mice.
Alexander JJ; Zwingmann C; Jacob A; Quigg R
Biochim Biophys Acta; 2007 Oct; 1772(10):1143-9. PubMed ID: 17942282
[TBL] [Abstract][Full Text] [Related]
2. MRL/lpr mice have alterations in brain metabolism as shown with [1H-13C] NMR spectroscopy.
Alexander JJ; Zwingmann C; Quigg R
Neurochem Int; 2005 Jul; 47(1-2):143-51. PubMed ID: 15893408
[TBL] [Abstract][Full Text] [Related]
3. Excessive matrix accumulation in the kidneys of MRL/lpr lupus mice is dependent on complement activation.
Bao L; Zhou J; Holers VM; Quigg RJ
J Am Soc Nephrol; 2003 Oct; 14(10):2516-25. PubMed ID: 14514729
[TBL] [Abstract][Full Text] [Related]
4. Up-regulation of transcription factor Blimp1 in systemic lupus erythematosus.
Luo J; Niu X; Liu H; Zhang M; Chen M; Deng S
Mol Immunol; 2013 Dec; 56(4):574-82. PubMed ID: 23911415
[TBL] [Abstract][Full Text] [Related]
5. Absence of functional alternative complement pathway alleviates lupus cerebritis.
Alexander JJ; Jacob A; Vezina P; Sekine H; Gilkeson GS; Quigg RJ
Eur J Immunol; 2007 Jun; 37(6):1691-701. PubMed ID: 17523212
[TBL] [Abstract][Full Text] [Related]
6. The parasitic worm product ES-62 targets myeloid differentiation factor 88-dependent effector mechanisms to suppress antinuclear antibody production and proteinuria in MRL/lpr mice.
Rodgers DT; McGrath MA; Pineda MA; Al-Riyami L; Rzepecka J; Lumb F; Harnett W; Harnett MM
Arthritis Rheumatol; 2015 Apr; 67(4):1023-35. PubMed ID: 25546822
[TBL] [Abstract][Full Text] [Related]
7. The selective p38 mitogen-activated protein kinase inhibitor, SB203580, improves renal disease in MRL/lpr mouse model of systemic lupus.
Jin N; Wang Q; Zhang X; Jiang D; Cheng H; Zhu K
Int Immunopharmacol; 2011 Sep; 11(9):1319-26. PubMed ID: 21549858
[TBL] [Abstract][Full Text] [Related]
8. Resetting the epigenetic histone code in the MRL-lpr/lpr mouse model of lupus by histone deacetylase inhibition.
Garcia BA; Busby SA; Shabanowitz J; Hunt DF; Mishra N
J Proteome Res; 2005; 4(6):2032-42. PubMed ID: 16335948
[TBL] [Abstract][Full Text] [Related]
9. Interleukin 6 (IL-6) deficiency delays lupus nephritis in MRL-Faslpr mice: the IL-6 pathway as a new therapeutic target in treatment of autoimmune kidney disease in systemic lupus erythematosus.
Cash H; Relle M; Menke J; Brochhausen C; Jones SA; Topley N; Galle PR; Schwarting A
J Rheumatol; 2010 Jan; 37(1):60-70. PubMed ID: 19955044
[TBL] [Abstract][Full Text] [Related]
10. Deposition of chromatin-IgG complexes in skin of nephritic MRL-lpr/lpr mice is associated with increased local matrix metalloprotease activities.
Hedberg A; Fismen S; Fenton KA; Mortensen ES; Rekvig OP
Exp Dermatol; 2010 Aug; 19(8):e265-74. PubMed ID: 20500770
[TBL] [Abstract][Full Text] [Related]
11. Glomerular Injury Is Exacerbated in Lupus-Prone MRL/lpr Mice Treated with a Protease-Activated Receptor 2 Antagonist.
Itto R; Oe Y; Imaruoka K; Sato E; Sekimoto A; Yamakage S; Kumakura S; Sato H; Ito S; Takahashi N
Tohoku J Exp Med; 2019 Oct; 249(2):127-133. PubMed ID: 31666446
[TBL] [Abstract][Full Text] [Related]
12. Administration of the soluble complement inhibitor, Crry-Ig, reduces inflammation and aquaporin 4 expression in lupus cerebritis.
Alexander JJ; Bao L; Jacob A; Kraus DM; Holers VM; Quigg RJ
Biochim Biophys Acta; 2003 Nov; 1639(3):169-76. PubMed ID: 14636948
[TBL] [Abstract][Full Text] [Related]
13. Signaling through up-regulated C3a receptor is key to the development of experimental lupus nephritis.
Bao L; Osawe I; Haas M; Quigg RJ
J Immunol; 2005 Aug; 175(3):1947-55. PubMed ID: 16034139
[TBL] [Abstract][Full Text] [Related]
14. Oridonin ameliorates lupus-like symptoms of MRL(lpr/lpr) mice by inhibition of B-cell activating factor (BAFF).
Zhou L; Sun L; Wu H; Zhang L; Chen M; Liu J; Zhong R
Eur J Pharmacol; 2013 Sep; 715(1-3):230-7. PubMed ID: 23712004
[TBL] [Abstract][Full Text] [Related]
15. Aberrant expression pattern of histone acetylation modifiers and mitigation of lupus by SIRT1-siRNA in MRL/lpr mice.
Hu N; Long H; Zhao M; Yin H; Lu Q
Scand J Rheumatol; 2009; 38(6):464-71. PubMed ID: 19922023
[TBL] [Abstract][Full Text] [Related]
16. C5a receptor deficiency attenuates T cell function and renal disease in MRLlpr mice.
Wenderfer SE; Ke B; Hollmann TJ; Wetsel RA; Lan HY; Braun MC
J Am Soc Nephrol; 2005 Dec; 16(12):3572-82. PubMed ID: 16207826
[TBL] [Abstract][Full Text] [Related]
17. Transgenic expression of a soluble complement inhibitor protects against renal disease and promotes survival in MRL/lpr mice.
Bao L; Haas M; Boackle SA; Kraus DM; Cunningham PN; Park P; Alexander JJ; Anderson RK; Culhane K; Holers VM; Quigg RJ
J Immunol; 2002 Apr; 168(7):3601-7. PubMed ID: 11907125
[TBL] [Abstract][Full Text] [Related]
18. L-arginine supplementation accelerates renal fibrosis and shortens life span in experimental lupus nephritis.
Peters H; Border WA; Rückert M; Krämer S; Neumayer HH; Noble NA
Kidney Int; 2003 Apr; 63(4):1382-92. PubMed ID: 12631354
[TBL] [Abstract][Full Text] [Related]
19. Activated protein C attenuates systemic lupus erythematosus and lupus nephritis in MRL-Fas(lpr) mice.
Lichtnekert J; Rupanagudi KV; Kulkarni OP; Darisipudi MN; Allam R; Anders HJ
J Immunol; 2011 Sep; 187(6):3413-21. PubMed ID: 21849682
[TBL] [Abstract][Full Text] [Related]
20. A benzenediamine derivative fc-99 attenuates lupus-like syndrome in MRL/lpr mice related to suppression of pDC activation.
Ji J; Fan H; Li F; Li X; Dong G; Gong W; Song Y; Liu F; Hua C; Tan R; Dou H; Hou Y
Immunol Lett; 2015 Dec; 168(2):355-65. PubMed ID: 26545567
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
